FDA declines to approve Pfizer's biosimilar to Roche's cancer drug

(Reuters) - Pfizer Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve the company's biosimilar to Roche's breast cancer drug, Herceptin, and sought additional technical information.